Cargando…

Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib

Ruxolitinib is a Janus kinase (JAK)1 and JAK2 inhibitor approved for the treatment of myelofibrosis and for polycythemia patients who are resistant or intolerant to hydroxyurea. We report a 72 year-old man patient with polycythemia vera who developed multiple cutaneous squamous cell carcinomas (cSCC...

Descripción completa

Detalles Bibliográficos
Autores principales:	March-Rodriguez, Álvaro, Bellosillo, Beatriz, Álvarez-Larrán, Alberto, Besses, Carles, Pujol, Ramon M, Toll, Agustí
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Dermatological Association; The Korean Society for Investigative Dermatology 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992689/ https://www.ncbi.nlm.nih.gov/pubmed/33911570 http://dx.doi.org/10.5021/ad.2019.31.2.204

Ejemplares similares

MiR-204 silencing in intraepithelial to invasive cutaneous squamous cell carcinoma progression
por: Toll, Agustí, et al.
Publicado: (2016)

Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing
por: Angona, A, et al.
Publicado: (2016)

Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib
por: Aboul-Fettouh, Nader, et al.
Publicado: (2018)

miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia
por: Navarro, A, et al.
Publicado: (2016)

Heinz-Lippmann disease as an underrecognized cause of chronic venous insufficiency-associated cutaneous ulcers: Clinical and imaging findings
por: Toll, Agustí, et al.
Publicado: (2020)

Ruxolitinib cream for the treatment of cutaneous sarcoidosis
por: Smith, Jeffrey S., et al.
Publicado: (2023)

Treatment of cutaneous lupus with topical ruxolitinib cream
por: Park, Jonathan J., et al.
Publicado: (2022)

Aggressive cutaneous squamous cell carcinoma of the scalp
por: Suk, Sangwoo, et al.
Publicado: (2020)

Rapid Growing Superficial Cutaneous Leiomyosarcoma of the Face
por: Lee, Kwang Chul, et al.
Publicado: (2013)

Rapidly growing cutaneous nodules in a sheep worker
por: Garcia-Arpa, Monica, et al.
Publicado: (2020)

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Diagnostic Value of Genotypic Analysis in Primary Cutaneous Lymphomas using Standardized BIOMED-2 Polymerase Chain Reaction Protocols: Experience in Daily Clinical Practice
por: LÓPEZ AVENTÍN, Daniel, et al.
Publicado: (2021)

Rapidly Growing Squamous Cell Carcinoma of the Tongue
por: Myers, Dominick, et al.
Publicado: (2020)

Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma
por: Karagianni, Fani, et al.
Publicado: (2021)

The Distinctive Features behind the Aggressiveness of Oral and Cutaneous Squamous Cell Carcinomas
por: Alonso-Juarranz, Miguel, et al.
Publicado: (2023)

Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Review
por: Desai, Neha, et al.
Publicado: (2023)

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
por: Barbui, Tiziano, et al.
Publicado: (2021)

Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
por: Alvarez‐Larrán, Alberto, et al.
Publicado: (2022)

Identification of differentially expressed genes in actinic keratosis samples treated with ingenol mebutate gel
por: Segura, Sonia, et al.
Publicado: (2020)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Inefficient differentiation response to cell cycle stress leads to genomic instability and malignant progression of squamous carcinoma cells
por: Alonso-Lecue, Pilar, et al.
Publicado: (2017)

Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA
por: Garcia-Gisbert, Nieves, et al.
Publicado: (2022)

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
por: Ayala, Rosa, et al.
Publicado: (2023)

Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Study of Regulatory T-Cells in Patients with Gastric Malt Lymphoma: Influence on Treatment Response and Outcome
por: García, Mar, et al.
Publicado: (2012)

Ruxolitinib: Thrombocytopenia following compassionate use of ruxolitinib: 2 case reports
Publicado: (2022)

P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS
por: Harrison, C., et al.
Publicado: (2022)

Identification of Two Novel EPOR Gene Variants in Primary Familial Polycythemia: Case Report and Literature Review
por: Lo Riso, Laura, et al.
Publicado: (2022)

Extraordinarily aggressive cutaneous sarcomatoid squamous cell carcinoma of the face: a case report
por: Lee, Yunjae, et al.
Publicado: (2022)

Ruxolitinib Treatment During Myelofibrosis Leads to Cutaneous Mycobacterium marinum Infection: A Case Report
por: Chen, Xiaonan, et al.
Publicado: (2023)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Polycythemia Vera and Essential Thrombocythemia Patients Exhibit Unique Serum Metabolic Profiles Compared to Healthy Individuals and Secondary Thrombocytosis Patients
por: Gómez-Cebrián, Nuria, et al.
Publicado: (2021)

Metastatic Calcinosis Cutis Secondary to Selective Fibroblast Growth Factor Receptor Inhibitor: Rapid and Complete Regression after Blood Phosphate Normalization and Drug Withdrawal
por: LOPEZ-CASTILLO, Daniel, et al.
Publicado: (2020)

A case of head and neck cutaneous squamous cell carcinoma highlighting aggressive perineural features
por: Kalil, Grant H., et al.
Publicado: (2022)

Rapid response to cemiplimab for advanced cutaneous squamous cell carcinoma
por: Zargham, Hanieh, et al.
Publicado: (2022)

Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing
por: Ferrer-Marín, Francisca, et al.
Publicado: (2013)

Effects of COVID-19 Lockdown on Tumour Burden of Melanoma and Cutaneous Squamous Cell Carcinoma
por: TEJERA-VAQUERIZO, Antonio, et al.
Publicado: (2021)

A photo-distributed papulopustular eruption and multiple squamous cell carcinomas in a patient on ruxolitinib
por: Khanna, Urmi, et al.
Publicado: (2019)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tv0n04vofvbhfbh6nvesoahaaj